• BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis 

      Rustad, Even Holth; Dai, Hong Yan; Hov, Håkon; Coward, Eivind; Beisvag, Vidar; Myklebost, Ola; Hovig, Eivind; Nakken, Sigve; Vodak, Daniel; Meza-Zepeda, Leonardo A.; Sandvik, Arne Kristian; Wader, Karin Fahl; Misund, Kristine; Sundan, Anders; Aarset, Harald; Waage, Anders (Journal article; Peer reviewed, 2015)
      In this study, we analyzed the prevalence and clone size of BRAF V600E mutation in 209 patients with multiple myeloma and related the results to clinical phenotype, response and survival. Biopsies were screened for BRAF ...
    • Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines 

      Giliberto, Mariaserena; Miranda Santana, Leonardo; Holien, Toril; Misund, Kristine; Nakken, Sigve; Vodak, Daniel; Hovig, Eivind; Meza, Leonardo Zepeda; Coward, Eivind; Waage, Anders; Tasken, Kjetil; Skånland, Sigrid S (Peer reviewed; Journal article, 2022)
      Introduction: Multiple myeloma (MM) is a heterogeneous disease where cancer-driver mutations and aberrant signaling may lead to disease progression and drug resistance. Drug responses vary greatly, and there is an unmet ...